Pulmonary Embolism Drugs Market Players:
- Janssen Global Services, LLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Abbott Laboratories
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- Daiichi Sankyo Company, Limited
- Siemens Healthcare GmbH
- Baxter International Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of pulmonary embolism drugs is estimated at USD 1.95 billion.
The global pulmonary embolism drugs market size was more than USD 1.85 billion in 2025 and is anticipated to grow at a CAGR of over 6.1%, reaching USD 3.34 billion revenue by 2035.
The North America pulmonary embolism drugs market is anticipated to command the majority share by 2035, driven by rising healthcare expenditure supported by escalating government spending to strengthen healthcare services.
Key players in the market include Water Office, ACCIONA, Harbin ROPV Industrial Co LTD, TotalEnergies SE, SUEZ, LG Nano H2O Inc, ACWA Power, Vontron Membrane Technology, Solar Water Solutions Ltd., Sinovoltaics Group.
